Cancer immunotherapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

22 citing papers in PubMed.

1. Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha.Cancer immunology, immunotherapy : CII · 2011
   Trial
2. Targeting immunosuppressive network in glioblastoma: Emerging strategies to overcome immunodeficiency and enhance therapeutic efficacy.Acta pharmaceutica Sinica. B · 2026
   Review
3. Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders.Molecules (Basel, Switzerland) · 2023
   Review
4. Nanomedicine-based immunotherapy for central nervous system disorders.Acta pharmacologica Sinica · 2020
   Review
5. Defective HLA class I antigen processing machinery in cancer.Cancer immunology, immunotherapy : CII · 2018
   Article
6. Survivin-Based Treatment Strategies for Squamous Cell Carcinoma.International journal of molecular sciences · 2018
   Review
7. Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: a meta-analysis.Oncotarget · 2017
   Article
8. The Role of Tumor Microenvironment in Cancer Immunotherapy.Advances in experimental medicine and biology · 2017
   Review
9. Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells inhibits NK cell-mediated killing through LLT1-NKRP1A (CD161) interaction.Oncotarget · 2016
   Article
10. Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens.Frontiers in immunology · 2015
    Review
11. Adenoviral-based immunotherapy provides local disease control in an orthotopic murine model of esophageal cancer.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2014
    Article
12. Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells.Breast cancer research and treatment · 2013
    Article
13. Death receptor-independent activation-induced cell death in human melanoma antigen-specific MHC class I-restricted TCR-engineered CD4 T cells.Journal of immunology (Baltimore, Md. : 1950) · 2013
    Article
14. Elimination of metastatic melanoma using gold nanoshell-enabled photothermal therapy and adoptive T cell transfer.PloS one · 2013
    Article
15. Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance.American journal of clinical and experimental immunology · 2013
    Article
16. Molecular insights for optimizing T cell receptor specificity against cancer.Frontiers in immunology · 2013
    Article
17. Val-boroPro accelerates T cell priming via modulation of dendritic cell trafficking resulting in complete regression of established murine tumors.PloS one · 2013
    Article
18. Development of tumor-infiltrating CD8+ T cell memory precursor effector cells and antimelanoma memory responses are the result of vaccination and TGF-β blockade during the perioperative period of tumor resection.Journal of immunology (Baltimore, Md. : 1950) · 2011
    Article
19. Transduction of SIV-specific TCR genes into rhesus macaque CD8+ T cells conveys the ability to suppress SIV replication.PloS one · 2011
    Article
20. Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death.Cancer research · 2009
    Article

Corrections and comments

• Comment on
  Cancer immunology.2008

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as